Latest Board Renewal News

Page 11 of 11

Rhythm Biosciences Accelerates Growth with $3.2M R&D Return and Genetype Acquisition

Rhythm Biosciences reported a strong December quarter, securing a $3.2 million R&D tax incentive and completing a strategic acquisition of Genetype assets, positioning the company for commercial expansion in cancer diagnostics.

Ada Torres

23 Jan 2025

Top